n3 PUFA and Muscle-disuse Atrophy in Older Women

Inclusion Criteria: * Female * Aged 55 - 75 years old * non-smoking (for at least 2 years) * \> 5 years post-menopausal * Body mass index (BMI) between 22 and 33 kg/m2 * Mini-Mental State Exam (MMSE) score \> 20 * Acceptable medications include: Angiotensin Converting Enzyme (ACE), Beta-Blockers, Acetylsalicylic Acid, Calcium Channel blockers, Depression/Anxiety meds, Bisphosphonates (Fosamax®, Didrocal®, Actonel®, Aclasta®). Exclusion Criteria: * Any concurrent medical, orthopedic, or psychiatric condition that, in the opinion of the Investigators, would compromise the ability to comply with the study requirements. * History of cancer within the last 5 years, except basal cell carcinoma, non-squamous skin carcinoma, prostate cancer, or carcinoma in situ with no significant progression over the past 2 years. * Significant orthopedic, cardiovascular, pulmonary, renal, liver, infectious disease, immune disorder, or metabolic/endocrine disorders or other disease that would preclude oral n-3 PUFA supplement ingestion and/or assessment of safety and study objectives * Current illnesses which could interfere with the study (e.g. prolonged severe diarrhea, regurgitation, difficulty swallowing) * Participation in a study of an investigational product less than 60 days or 5 half-lives of the investigational product, whichever is longer, before enrollment in this study * Hypersensitivity to the test product * Excessive alcohol consumption (\>21 units/week) * Prior gastrointestinal b…